Issue link: http://www.e-digitaleditions.com/i/197544
H D I N S I G H T S Clinical Trials Status Report SPONSOR STUDY AGENT PHASE PRINCIPAL INVESTIGATOR, CONTACT DESIGN New York Medical College Tetrabenazine IV Robert Fekete, MD 914-594-4293 Prospective case-control study to compare Stroop Visual Interference Scores while individuals who are already taking tetrabenazine are off the drug for three days and then back on the drug National Institute of Neurological Disorders and Stroke Coenzyme Q10 III Auspex Pharmaceuticals, Inc. SD-809 Extended Release III Auspex Pharmaceuticals, Inc. SD-809 Extended Release III National Center for Complementary and Alternative Medicine Creatine III Assistance Publique Hôpitaux de Paris Olanzapine, Tetrabenazine and Tiapride III Raptor Pharmaceuticals Cysteamine Bitartrate Delayed-release Capsules (RP103) II/III National Institute of Neurological Disorders and Stroke Coenzyme Q10 II Charite University Epigallocatechin Gallate II Teva Pharmaceutical Industries Pridopidine II Prana Biotechnology PBT2 II Pfizer PF-0254920 II Pfizer CT.gov Call Center, 800-718-1021 Randomized double-blind study testing the efficacy and tolerability of PF-0254920 in changing the total motor score patients with HD Charite University Bupropion II Josef Priller, MD +49 (0)30 450 617209 Randomized double-blind study testing the efficacy and tolerability of Bupropion in changing apathy in patients with HD Randomized double-blind study to see Merit Cudkowicz, whether coenzyme Q10 is effective in slowing MD, MSc Samuel Frank, MD Randomized double blind study to determine 800-487-7671 whether SD-809 ER tablets are effective in the treatment of chorea associated with HD Samuel Frank, MD Open-label, long term safety study of SD-809 ER 800-487-7671 800-487-7671 Randomized double blind study to test whether high-dose creatine can slow the progressive functional decline that occurs in adult persons with early clinical features of HD Anne-Catherine Randomized controlled study to compare the Bachoud Levi, PhD beneficial and adverse effects of 3 different neuroleptics in HD +33 (0)1 49 81 23 01 Christophe Verny, Double-blind, placebo-controlled study to be followed by an open-label extension study MD Randomized double blind study testing the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in preElaine M Julian-Baros, manifest participants carrying the CAGn BS: 585-273-2879 expansion for HD Christopher Ross, MD, PhD, Josef Priller, MD +49 (0)30 450 617209 Randomized double blind study testing the efficacy and tolerability of (2)epigallocatechin-3-gallate (EGCG) in changing cognitive function in patients with HD Karl Kieburtz, MD Open label, single group assignment study to assess the long-term safety of 45 mg of MPH 5 years 12 weeks 58 weeks 3 years Randomized, double-blind safety and Ray Dorsey, MD 800-487-7671 (U.S.) tolerability study of PBT2 of individuals with mild to moderate HD 800-794-669 (Australia) SITES STATUS 1 site Currently enrolling Terence Cardinal Cooke Health Care Center 49 sites U.S., Canada, Australia 7 sites U.S. Enrollment complete, active study 7 sites U.S. Recruiting Recruiting 52 sites Currently enrolling U.S., Canada, Australia, New Zealand 1 year 1 site Europe Currently enrolling 18 months 8 total France Study complete, results pending 13 sites United States Study complete, results pending 4 sites Germany Currently enrolling 22 sites U.S. and Canada Enrollment complete, active study 20 sites Australia and U.S. Study complete, results pending N/A Not yet open for patient enrollment 3 sites Germany Currently enrolling 20 weeks 1 year 2 years pridopidine in HD participants Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/ HD Insights, Vol. 6 6 hours the worsening of symptoms of HD 800-487-7671 Steven M Hersch, MD, PhD TRIAL LENGTH 6 months 28 days 10 weeks To update or add a clinical trial, please e-mail editor@hdinsights.org. Copyright © Huntington Study Group 2013. All rights reserved. 7